TScan Therapeutics, Inc.
TCRX
$0.95
-$0.07-6.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.42M | 6.96M | 4.42M | 2.82M | 9.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.42M | 6.96M | 4.42M | 2.82M | 9.36M |
| Cost of Revenue | 20.96M | 15.53M | 9.78M | 4.85M | 15.13M |
| Gross Profit | -12.54M | -8.57M | -5.36M | -2.03M | -5.76M |
| SG&A Expenses | 33.63M | 33.16M | 31.84M | 30.29M | 28.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 157.09M | 151.20M | 144.12M | 137.64M | 128.83M |
| Operating Income | -148.67M | -144.24M | -139.70M | -134.82M | -119.47M |
| Income Before Tax | -142.60M | -136.78M | -131.48M | -127.50M | -111.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -142.60 | -136.78 | -131.48 | -127.50 | -111.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -142.60M | -136.78M | -131.48M | -127.50M | -111.30M |
| EBIT | -148.67M | -144.24M | -139.70M | -134.82M | -119.47M |
| EBITDA | -145.81M | -141.12M | -136.17M | -130.71M | -114.79M |
| EPS Basic | -2.52 | -2.45 | -2.39 | -2.42 | -2.20 |
| Normalized Basic EPS | -1.56 | -1.52 | -1.48 | -1.50 | -1.37 |
| EPS Diluted | -2.52 | -2.45 | -2.39 | -2.42 | -2.20 |
| Normalized Diluted EPS | -1.56 | -1.52 | -1.48 | -1.50 | -1.37 |
| Average Basic Shares Outstanding | 226.68M | 223.28M | 219.47M | 210.78M | 202.02M |
| Average Diluted Shares Outstanding | 226.68M | 223.28M | 219.47M | 210.78M | 202.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |